BPI-16350
- Generic Name
- BPI-16350
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT05433480
- Locations
- 🇨🇳
Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China
🇨🇳Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China
🇨🇳Inner Mongolia People's Hospital, Hohhot, Neimenggu, China
A Food-Effect Study of BPI-16350 in Healthy Subjects
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05316259
- Locations
- 🇨🇳
Kthics Committee (seal),of Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03791112
- Locations
- 🇨🇳
Betta Pharmaceuticals Co., Hangzhou, Zhejiang Provice, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath